公开(公告)号：US12213961B2

公开(公告)日：2025-02-04

申请号：US18513181

申请日：2023-11-17

Applicant: VICORE PHARMA AB

Inventor： Carl-Johan Dalsgaard ,  Rohit Batta

IPC: A61K31/4178 ,  A61K9/48 ,  A61P1/00 ,  A61P11/00

Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

公开(公告)号：US20210386712A1

公开(公告)日：2021-12-16

申请号：US17458886

申请日：2021-08-27

Applicant: VICORE PHARMA AB

Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

IPC: A61K31/4178 ,  A61K38/21 ,  A61K31/513 ,  A61K31/706 ,  A61P31/14 ,  A61K31/573 ,  A61K31/16 ,  A61K45/06 ,  A61K31/7056

Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-thiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

公开(公告)号：US11819494B2

公开(公告)日：2023-11-21

申请号：US17680654

申请日：2022-02-25

Applicant: VICORE PHARMA AB

Inventor： Carl-Johan Dalsgaard ,  Rohit Batta

IPC: A61K31/4178 ,  A61K9/48 ,  A61P11/00 ,  A61P1/00

CPC classification number: A61K31/4178 ,  A61K9/485 ,  A61K9/4858 ,  A61P1/00

Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

公开(公告)号：US20210290596A1

公开(公告)日：2021-09-23

申请号：US17113416

申请日：2020-12-07

Applicant: Vicore Pharma AB

Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

IPC: A61K31/4178 ,  A61K45/06 ,  A61K31/573 ,  A61K38/21 ,  A61K31/706 ,  A61K31/16 ,  A61K31/7056 ,  A61K31/513 ,  A61P31/14

Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

公开(公告)号：US12128029B2

公开(公告)日：2024-10-29

申请号：US18391451

申请日：2023-12-20

Applicant: VICORE PHARMA AB

Inventor： Carl-Johan Dalsgaard ,  Rohit Batta

IPC: A61K31/4178 ,  A61K9/48 ,  A61P1/00 ,  A61P11/00

CPC classification number: A61K31/4178 ,  A61K9/485 ,  A61K9/4858 ,  A61P1/00 ,  A61P11/00

Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

公开(公告)号：US20240207231A1

公开(公告)日：2024-06-27

申请号：US18352807

申请日：2023-07-14

Applicant: Vicore Pharma AB ,  Alex Therapeutics AB

Inventor： Johan RAUD ,  Carl-Johan Dalsgaard ,  Jessica Shull ,  Kimmy Bolke ,  Oliver Fleetwood

IPC: A61K31/4178 ,  A61B5/16 ,  A61K31/137 ,  A61K31/138 ,  A61K31/195 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/5575 ,  A61P11/00

CPC classification number: A61K31/4178 ,  A61B5/165 ,  A61K31/137 ,  A61K31/138 ,  A61K31/195 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/5575 ,  A61P11/00 ,  G16H20/70

Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).

公开(公告)号：US11123329B1

公开(公告)日：2021-09-21

申请号：US17113416

申请日：2020-12-07

Applicant: Vicore Pharma AB

Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

IPC: A61K31/4178 ,  A61P31/14 ,  A61K31/16 ,  A61K31/573 ,  A61K38/21 ,  A61K45/06 ,  A61K31/513 ,  A61K31/7056 ,  A61K31/706

Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.